Tonix Pharmaceuticals Holding (TNXP) Equity Average: 2023-2025
Historic Equity Average for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $199.6 million.
- Tonix Pharmaceuticals Holding's Equity Average rose 243.16% to $199.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.6 million, marking a year-over-year increase of 243.16%. This contributed to the annual value of $122.5 million for FY2024, which is N/A change from last year.
- As of Q3 2025, Tonix Pharmaceuticals Holding's Equity Average stood at $199.6 million, which was up 14.57% from $174.2 million recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's Equity Average ranged from a high of $199.6 million in Q3 2025 and a low of $58.2 million during Q3 2024.
- Over the past 3 years, Tonix Pharmaceuticals Holding's median Equity Average value was $121.9 million (recorded in 2023), while the average stood at $127.8 million.
- Per our database at Business Quant, Tonix Pharmaceuticals Holding's Equity Average crashed by 55.49% in 2024 and then skyrocketed by 243.16% in 2025.
- Over the past 3 years, Tonix Pharmaceuticals Holding's Equity Average (Quarterly) stood at $113.2 million in 2023, then decreased by 5.56% to $106.9 million in 2024, then soared by 243.16% to $199.6 million in 2025.
- Its Equity Average stands at $199.6 million for Q3 2025, versus $174.2 million for Q2 2025 and $160.0 million for Q1 2025.